Long-term health and quality of life after CD19 CAR T-cell therapy in B-ALL survivors
Official title: CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
Run by St. Jude Children's Research Hospital · NCT07048535 · Data updated 2026-11-12
This project will test whether standardized health checks can be done for children, adolescents, and young adults who are at least two years past CD19 CAR T-cell treatment for B-ALL.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Drugs / interventions | CAR T, chimeric antigen receptor |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | October 24, 2025 |
| Main results expected | July 2028 |
| Study ends | July 2029 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07048535 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people who received a single CD19-containing CAR T-cell product for B-ALL at age 26 or younger, are in sustained remission (allowing for one hematopoietic cell transplant), and are at least two years after their most recent CAR infusion.
✕Probably not a fit
Patients unlikely to benefit include those who are less than two years post-CAR infusion, who received non-CD19 or multiple different CAR products, who are not in sustained remission, or who cannot provide consent or travel for in-person testing.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
St. Jude is running a prospective, observational program to recruit pediatric, adolescent, and young adult B-ALL survivors who are at least two years after receiving a CD19-containing CAR T-cell product. Participants will undergo comprehensive, standardized assessments including medical history and physical exam, laboratory studies, brain MRI, neurocognitive testing, physical performance testing, and immune function testing. The effort leverages the St. Jude Lifetime Cohort (SJLIFE) infrastructure to harmonize procedures and test feasibility of multi-institutional late-effects surveillance. The primary focus is on characterizing persistent and new late-onset health conditions, neurologic and neurocognitive outcomes, immune status, and functional performance after CAR T-cell therapy.
Why it matters
Potential benefit: If successful, the program could identify previously unrecognized late health problems and inform follow-up care to improve long-term quality of life for B-ALL survivors treated with CD19 CAR T-cells.
How similar studies have gone: While long-term survivorship cohorts exist for childhood cancers, studies specifically describing late effects after CD19 CAR T-cell therapy are limited and this multi-center CAR T-focused follow-up is largely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≤ 26-years old at the time of the first CAR treatment * Receipt of a CD19-containing CAR T-cell product (investigational or commercial) for B- ALL * Receipt of one unique CAR product (reinfusion of same product allowed) * Sustained remission without subsequent therapy post-CAR (exception= post-CAR consolidative HCT) * Receipt of only one prior HCT (inclusive of pre- or post-CAR) * ≥ 2-years post last CAR T-cell infusion Exclusion Criteria: * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
Where it's running
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Aimee Talleur, MD — St. Jude Children's Research Hospital
- Study coordinator: Aimee Talleur, MD
- Email: referralinfo@stjude.org
- Phone: 888-226-4343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.
-
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.
-
Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T
This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.
-
CD7 CAR T-Cell Therapy for T-Cell Lymphomas
This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.
-
Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma
This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.
-
Loncastuximab tesirine plus rituximab as bridging therapy before CAR-T for relapsed or refractory large B‑cell lymphoma
This trial tries loncastuximab tesirine with rituximab as a bridge before commercial CD19 CAR‑T therapy for adults with relapsed or refractory large B‑cell lymphoma to see if it is safe and helps control disease before CAR‑T.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.